Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Alida Bio is a life science tools company specializing in the field of epitranscriptomics, developing innovative solutions for the study of RNA modifications. The company’s proprietary EpiPlex platform enables the multiplexed detection of various RNA modifications, such as m6A and pseudouridine, at single-base resolution across the entire transcriptome. By streamlining complex epitranscriptomic workflows into standard next-generation sequencing (NGS) processes, Alida Bio allows researchers to gain deep insights into RNA regulation even with low sample input. Their technology is designed to accelerate discovery in areas such as oncology, immunology, and neuroscience, where RNA modifications are recognized as critical drivers of disease. Alida Bio’s kits and integrated bioinformatics tools provide a scalable and sensitive approach to mapping the epitranscriptome for both academic and clinical research applications.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Alida Bio.